drugset
drugset / Trial / NCT03487562

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects

NCT03487562 ↗

Phase 1 Completed 48 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupOpen-labelBasic science

Summary

This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after administrations of DWP14012 alone and combinations of DWP14012, Clarithromycin and Amoxicillin in healthy male subjects

Timeline

Start
2018-04-08
Primary completion
2019-01-11
Completion
2019-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — —
Subject Amoxicillin Other / unclassified 1 g —
Subject Clarithromycin Small molecule 500 mg —
Background Lansoprazole Other / unclassified 30 mg —

Indications

No indication recorded.